International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Shingles Virus: A Complete Review of Pathogenesis, Diagnosis, and Treatment

Rutika Bhausaheb More[1], Damini Nanaji Nikam[2], Samir Ananda Lambate[3], Sanket Dhiraj More[4], Darshan Kailas Patil[5]

[1,2,3,4,5]Bachelor's Pharmacy at Swami Institute of Pharmacy, Abhona

Abstract:
The varicella-zoster virus, or VZV, is a neurotropic human herpesvirus that is widespread throughout the world and belongs to the group Alphaherpesviridae. It is the root cause of varicella-induced chickenpox and shingles (Herpes Zoster [HZ]). The virus, which is spread by respiratory droplets or contact with active varicella lesions, is considered one of the most contagious illnesses. Herpetic neuralgia (HZ) can cause pain, ocular swelling, and possibly even irreversible or temporary blindness. Pain begins to subside in the second week following shingles, and it may persist long after the rash has healed. This can result in a difficult complication called postherpetic neurogynea (PHN). As one ages, the frequency and severity of PHN increase. Ninety percent of those who receive the two-dose immunization are able to avoid shingles and HZ.

Keywords: Pathophysiology, Etiology, Epidemiology, symptoms, Symptoms Progressions, diagnoses, laboratory test method, treatment, complications, prevention, vaccination, risk factors.

Introduction:
The varicella zoster virus (VZV) is the cause of both shingles (herpes zoster [HZ]) and chickenpox (varicella). Since more than a century ago, the connection between these two illnesses has been known, and it is founded on two findings: After a varicella infection, VZV can remain latent in human neurons for decades. To sustain latency, adequate VZV-specific cell mediated immunity (CMI) is required. After autopsies on HZ patients revealed ganglionitis, the segmental nature of HZ and its genesis in individual sensory ganglia were recognized in the early 20th century. Von Bokay first noted varicella instances in children exposed to adults with HZ in 1892. An examination of isolates from a patient who had varicella followed by HZ a few years later established a connection between varicella and HZ. The molecular profiles of these isolates were the same. Prior to the varicella vaccine being developed, there were 4 million cases of varicella annually in the United States, or 15–16 cases for every 1,000 people. Since the varicella vaccine was approved in the United States in 1995, there has been a 76–87% decrease in the frequency of varicella between 1995 and 2000. In the USA, there are more than a million cases of HZ annually, with a 30% lifetime attack rate estimated.[1] Viruses that cause varicella zoster or chickenpox remain dormant in the body for an extended period of time. The immune system always deteriorates with age, which may lead to the normally dormant virus reactivating and triggering Shingles. It is thought that zoster arises from the immune system's inability to stop the virus's latent replication. There is a considerable correlation between immunological state and the occurrence of herpes zoster. Shingles are infrequent in people who

have a strong immune system. The infection is not benign and can appear in different ways. Many herpes zoster patients experience postherpetic neuralgia, a condition that causes moderate to severe pain, long after their illness has cleared up.[2] Therefore, the risk of developing Shingles is higher in the elderly. Usually, it results in a blistering, excruciating rash that spreads to one side of the face or body. The common rash of shingles is excruciating and blistering, appearing as a band of blisters along the left or right side of the body, following a nerve pathway. It can appear on the head (including the eyes and ears), arms, thighs, or body. People frequently characterize the pain as shock-like, stabbing, searing, or aching. It could make it difficult to go about daily tasks including sleeping, walking, and getting dressed.

Pathophysiology of VZV:

Varicella-zoster virus (VZV) is a type of herpesvirus that causes chickenpox and remains dormant in nerve cells. The virus spreads through the air or by touching infected skin lesions.[3] After entering the body, VZV infects immune cells and nearby lymphoid tissues. The chickenpox rash appears 10-21 days later. Normally, the immune system controls the virus, but if the immune system weakens due to factors like medication, illness, malnutrition, stress, or aging, the virus can reactivate. During reactivation, the virus travels along nerve pathways, causing pain, sensory loss, and neurological issues. In some cases, muscle weakness can occur if motor nerves are affected. Rarely, the virus can also affect the lining of the brain and spinal cord, especially if the eye area is involved.[4]

Pathogenesis of VZV:



Fig. 1 Pathogenesis of VZV.[5]

To gain a deeper insight into the innate antiviral immune response to varicella-zoster virus (VZV), it is crucial to explore the pathogenesis of primary VZV infection (refer to Figure 1). The initial infection occurs when an individual is exposed to infectious fluid from vesicular lesions or inhales respiratory droplets from someone with chickenpox. It is thought that VZV first targets the epithelial mucosa of the upper respiratory tract, where it interacts with immune cells in the tonsils and surrounding lymphoid tissue. Dendritic cells (DCs) are believed to be the first immune cells infected in the respiratory mucosa, facilitating VZV's transmission to T cells in the tonsils through direct contact. This results in viremia, which may allow the virus to spread to internal organs. During the incubation period of approximately 14 to 16 days, symptoms are not present. The infection then progresses back to the respiratory mucosa and manifests on the skin, leading to symptoms. Notably, the infection of keratinocytes results in a vesiculopustular rash, causing highly contagious lesions to appear on the skin and mucous membranes, including in the mouth. The spread of VZV throughout the body during the primary infection is believed to be supported by the movement of infected T cells. This is corroborated by clinical findings showing that VZV was isolated from peripheral blood mononuclear cells (PBMCs) of immunocompetent individuals with chickenpox during the incubation phase and just before the vesicular rash appeared. Typically, the host's immune system clears primary varicella within one to two weeks; however, if the immune response is insufficient, VZV can disseminate to other areas, including the central nervous system (CNS) and lungs, leading to severe complications such as VZV encephalitis, cerebellar ataxia, demyelinating neuropathy, myelitis, and pneumonia. Despite a robust immune response during the initial infection, VZV is not completely eliminated from the body. Instead, the virus invades neurons in the sensory ganglia and establishes a lifelong latent infection. It likely reaches these ganglia via retrograde axonal transport from skin nerve endings and may also enter through immune cells. Furthermore, it is posited that VZV could establish latency in the enteric nervous system, which may clarify its connection to gastrointestinal issues.[6] To gain a deeper insight into the innate antiviral immune response to varicella-zoster virus (VZV), it is crucial to explore the pathogenesis of primary VZV infection (refer to Figure 1). The initial infection occurs when an individual is exposed to infectious fluid from vesicular lesions or inhales respiratory droplets from someone with chickenpox. It is thought that VZV first targets the epithelial mucosa of the upper respiratory tract, where it interacts with immune cells in the tonsils and surrounding lymphoid tissue. Dendritic cells (DCs) are believed to be the first immune cells infected in the respiratory mucosa, facilitating VZV's transmission to T cells in the tonsils through direct contact. This results in viremia, which may allow the virus to spread to internal organs. During the incubation period of approximately 14 to 16 days, symptoms are not present. The infection then progresses back to the respiratory mucosa and manifests on the skin, leading to symptoms. Notably, the infection of keratinocytes results in a vesiculopustular rash, causing highly contagious lesions to appear on the skin and mucous membranes, including in the mouth. The spread of VZV throughout the body during the primary infection is believed to be supported by the movement of infected T cells. This is corroborated by clinical findings showing that VZV was isolated from peripheral blood mononuclear cells (PBMCs) of immunocompetent individuals with chickenpox during the incubation phase and just before the vesicular rash appeared. Typically, the host's immune system clears primary varicella within one to two weeks; however, if the immune response is insufficient, VZV can disseminate to other areas, including the central nervous system (CNS) and lungs, leading to severe complications such as VZV encephalitis, cerebellar ataxia, demyelinating neuropathy, myelitis, and pneumonia.Despite a robust immune response during the initial infection, VZV is not completely eliminated from the body. Instead, the virus invades neurons in the

sensory ganglia and establishes a lifelong latent infection. It likely reaches these ganglia via retrograde axonal transport from skin nerve endings and may also enter through immune cells. Furthermore, it is posited that VZV could establish latency in the enteric nervous system, which may clarify its connection to gastrointestinal issues.[7]

Course of Illness:

Herpes zoster typically starts with intense unilateral pain that lasts for several days prior to the onset of the rash. This phase of herpes zoster is indicative of the pathology resulting from the multiplication and spread of reactivated varicella-zoster virus (VZV) within the affected sensory ganglion. The initial pain experienced in herpes zoster can resemble that of appendicitis, biliary or renal colic, cholecystitis, duodenal ulcer, glaucoma, myocardial infarction, pleurisy, or a herniated intervertebral disk, which can potentially lead to significant misdiagnosis. Diagnosis of herpes zoster is nearly impossible until the distinct vesicular dermatomal rash appears. Once the rash emerges, skin lesions develop in waves, quickly transforming from erythematous macules to papules and then to delicate intraepithelial vesicles filled with clear fluid. As polymorphonuclear leukocytes, macrophages, and lymphocytes infiltrate the vesicles, the fluid becomes cloudy and the vesicles turn into pustules. These pustules eventually dry, forming flat, adherent crusts. Vesicles and pustules generally remain for 7 to 10 days, and the crusts last for 2 to 3 weeks. Healing, or re-epithelialization, is usually complete within 4 weeks from the rash's appearance. However, pain, which peaks early in the second week, may continue even after the rash has healed, leading to a challenging complication known as postherpetic neuralgia (PHN).

Postherpetic Neuralgia:

Postherpetic Neuralgia (PHN) becomes more common and severe with increasing age, along with the likelihood of developing it after herpes zoster. The experience of PHN varies significantly among individuals; while no two patients describe it in the same way, many report it to be the most intense pain they have ever felt. R. Edgar Hope-Simpson first described clinically significant PHN in 1975 as persistent pain severe enough to disrupt daily activities, diminish quality of life, and prompt patients to seek medical help. This significant form of PHN often arises from more severe cases of herpes zoster, which are marked by intense pain and widespread rash during the acute phase. Patients with PHN typically present with a central area of skin scarring and sensory loss, encircled by regions of hypersensitivity and allodynia. This allodynia is particularly troubling as it causes non-painful stimuli, such as light touch, to trigger pain and discomfort. Most individuals with PHN experience allodynia, which contributes significantly to their disability. Even gentle touches, like that of clothing, can induce severe pain, severely impacting their quality of life and ability to perform everyday tasks—some may even find it too painful to dress or leave their homes.

Those suffering from prolonged PHN exhibit pathological signs of neuronal damage and scarring in the sensory ganglion and spinal dorsal horn that correspond to the affected skin area. Therefore, the loss of primary neurons in the sensory ganglion and damage to secondary neurons in the spinal cord's dorsal horn during the acute herpes zoster phase likely underlie many sensory issues associated with PHN.[8]

Etiology:

Chickenpox is transmitted through inhaling airborne droplets from an infected person. The virus is very contagious and can spread quickly. The initial infection occurs in the mucosal lining of the upper

respiratory tract. After 2 to 6 days, the virus enters the bloodstream, and another wave of viremia happens within 10 to 12 days. During this period, the typical vesicles develop. The body produces immunoglobulin antibodies (IgA, IgM, and IgG), but only IgG provides lifelong immunity. Following the primary infection, the varicella virus remains in sensory nerves and can reactivate later, causing shingles.[9]

The Varicella-Zoster Virus (VZV) is a neurotropic human herpes virus that falls under the alpha herpesviridae genus and is found globally. This virus is responsible for causing primary infections such as varicella (chickenpox) and can lead to herpes zoster (HZ), which represents the reactivation of a latent infection. The VZV genome comprises approximately 125,000 base pairs of linear double-stranded DNA and features a nucleocapsid made of 162 capsomers. This virus is notably cell-associated, targeting only human cells, including epithelial cells, T lymphocytes, and ganglionic neurons. The entry of the virus into neural cells is facilitated by heparin sulphate proteoglycan and the glycogen synthase kinase 3 (GSK-3) pathway. Core glycoproteins B, H, and L are involved in the core fusion complex, and new virus particles can begin to be released within 9 to 12 hours after infection. Varicella is notably one of the most contagious diseases, transmitted via respiratory droplets or contact with the lesions of active varicella. After initial replication in the respiratory tract, the virus proliferates in nearby lymph nodes, leading to viremia and resulting in cutaneous vesicular eruptions. These lesions can present in various stages, from early vesicles to crusted spots, and potentially scar. The incubation period for varicella can span 10 to 21 days, with contagiousness beginning one to four days before the rash appears and lasting until all lesions have crusted over. In pregnant women, varicella infection can be transmitted to the fetus through the placenta, which can lead to severe complications. Maternal vaccination provides some degree of protection for the fetus. Although HZ is infrequent among children, a study in Canada indicated that vaccination against varicella may lower the risk of developing HZ by 64% in children. However, childhood vaccination does not seem to affect the incidence of HZ in older age. After the primary infection, VZV can remain latent in nerve tissue, particularly in dorsal root ganglia, cranial nerve ganglia, various autonomic ganglia in the enteric nervous system, and astrocytes. The protein Nectin-1 is thought to facilitate viral invasion of axons and neuronal cell bodies due to its high expression in neurons. In VZV-infected neurons, anti-apoptotic proteins like Bcl2 and Bcl-XL show increased expression. There appears to be a correlation between VZV latency and open reading frame (ORF). During reactivation, VZV replicates in neuronal cell bodies, after which virus particles exit the cell bodies and move down the nerve to the corresponding dermatome. This movement leads to vesiculation and inflammation within that dermatome. The pain associated with HZ is a consequence of the inflammation affecting the VZV-infected nerves. However, HZ does not pose a risk to a developing fetus due to maternal antibodies transferred across the placenta.[10]

Epidemiology:

Studies have consistently shown that the incidence of herpes zoster (shingles) increases with age. In Korea, the incidence rate rose from 2.0 per 1,000 people per year in children to 21.8 per 1,000 people per year in those aged 70-79 years. The peak incidence occurred in the 60-69 age group, with a lower incidence in those over 80 years old. Hospitalization rates for shingles also increase with age, with older individuals experiencing more severe complications, longer hospital stays, and higher healthcare costs. Common complications requiring hospitalization include post-herpetic neuralgia, bacterial infections, and ocular involvement. Some studies suggest that vaccination against shingles should be recommended not only for individuals over 60 years but also for younger adults, considering the severity and chronicity of the disease.

The study of epidemiology Among the human alpha herpes viruses, varicella is mostly infected according to a regular winter-spring seasonality pattern when it is spread through the air. This makes VZV unique. Fomites from varicella and HZ skin lesions can also spread VZV. Because HZ is caused by the reactivation of each patient's latent endogenous virus, it does not follow a seasonal pattern and does not arise during epidemics. As a result, the incidence rate of HZ is typically more steady than that of varicella.



Fig: 1

Cases of varicella and HZ reported to the England and Wales Royal College of General Practitioners, 1967–92.8 Reproduced with permission from Miller E, Marshall R, and Vurdien J. Varicella-zoster infection: epidemiology, outcome, and control. 1993;4:222–230 in Rev Med Microbiol. With an incidence of roughly three cases per 1,000 patient-years and an inflection point at about age 50, the incidence of HZ rises with age. The incidence increases to roughly 10 instances per 1,000 patient-years by the age of 80.



Fig: 2

As people age, the incidence of HZ rises. Figure modified from Gauthier et al. (2009) and Edmunds et al. (2001).9, 10 Abbreviations: RCGP, the Royal College of General Practitioners; MSGP4, the Fourth Morbidity Survey in General Practice. In many temperate countries, varicella predominantly affects children under 10 years of age, and the incidence of HZ across these countries is very similar. In contrast, in many tropical countries, the incidence of varicella in children is low and the virus frequently occurs in late adolescence or early adulthood. Hence, the cumulative proportion of people who develop varicella approaches that of temperate climates by 30 years of age. There are no data available for the incidence of HZ in tropical countries.[11,12,13]

Shingles lesions and the accompanying pain, often characterized as burning, typically appear on skin areas served by one or two neighboring sensory nerves, almost exclusively on one side of the body. The skin lesions generally fade over several weeks, but the pain may linger longer. In 10–15% of instances, the pain lasts longer than three months, resulting in a chronic and frequently debilitating condition known as postherpetic neuralgia. Other serious complications arising from varicella zoster infection can include Mollaret's meningitis, zoster multiplex, and inflammation of brain arteries, which can lead to a stroke, myelitis, herpes ophthalmicus, or zoster sine herpete. In Ramsay Hunt syndrome, the virus affects the geniculate ganglion, causing lesions that follow particular branches of the facial nerve. Symptoms might involve painful blisters on the tongue and ear, as well as one-sided facial weakness and hearing loss. If infection occurs during early pregnancy, it can severely harm the fetus. Reye's syndrome may develop following the initial infection, leading to persistent vomiting and symptoms of brain dysfunction, such as severe drowsiness or aggressive behavior, with some cases resulting in coma or death. This syndrome predominantly impacts children and teenagers, and the risk increases if aspirin is taken during the infection.[14]

Symptoms:

Most Common Symptoms of Shingles

1. Typical symptoms of shingles include:

- Persistent dull,
- burning, or
- gnawing pain,
- sharp
- intermittent stabbing pain
- A rash that resembles chickenpox but is localized to specific areas
- Blisters filled with fluid that accompany the rash

2. Symptoms on the Body:

A blistering rash may occur in distinct bands, known as dermatomes, which are Areas of skin innervated by sensory nerves.

Common sites include:

- The chest
- The abdomen
- The back
- Areas around the waist

This rash usually appears on only one side of the body, depending on the affected dermatome.

2.1 Facial Symptoms:

If the rash is on the face, symptoms typically manifest on one side, generally around the eye and Forehead. These can include:

- Pain in the affected dermatome
- Rash
- Muscle weakness
- Headache

2.2 Eye Symptoms:

If the virus impacts the ophthalmic nerve, it can lead to herpes zoster ophthalmicus (HZO), resulting in pain, swelling around the eye, and potential temporary or permanent vision loss.

2.3 Ear Symptoms:

Shingles might also occur in or near the ear, leading to balance and hearing issues, along With facial muscle weakness on the affected side. These symptoms can be long-lasting or even Permanent. Anyone experiencing symptoms around the ears and eyes should seek immediate medical Help to minimize complications.

2.4 Mouth Symptoms:

When shingles affects the mouth, symptoms can include:-

Facial tender ness:

- Oral pain
- Toothache
- Lesions on the hard and soft palate

These issues can make eating or drinking uncomfortable.

2.5 Internal Shingles:

Shingles can also impact internal organs, often without a rash, leading to different Complications. Research has identified shingles within the digestive system, which may cause Gastrointestinal problems, and in the brain's arteries, potentially heightening the risk of stroke and Dementia.

3. Other Symptoms:

Additional symptoms may include:

- Fever
- Fatigue
- Chills
- Headache
- Nausea

Symptoms Progressions:

The progression of symptoms generally follows this order:

1. Pain, tingling, numbness, and itching in a specific skin area.
2. A rash appears within up to two weeks.
3. Red patches and itchy, fluid-filled blisters develop and last for 3-5 days.
4. Blisters may merge, forming a streak that resembles a severe burn, making even light touch painful.
5. Inflammation can occur in the soft tissues around the rash

6. After 7-10 days, the blisters begin to dry and form scabs. Though the blisters fade, they might leave Minor scarring.

Shingles typically last 2-4 weeks and are contagious until the blisters have dried and crusted. Most individuals will experience shingles only once, but it can recur in some cases. When to See a Doctor Prompt treatment after symptom onset can help reduce the duration and intensity of the infection. This Is especially vital for individuals over 60 or those with weakened immune systems, as they are at greater Risk for serious complications. If the rash spreads to other parts of the body or if other symptoms arise, such as a high fever, consulting A doctor is advisable. Additionally, anyone with a rash near the eye should seek immediate medical attention, as it can indicate HZO, which, if untreated, may lead to scarring, vision impairment, and permanent damage to the eye.

Diagnosis:

A shingles diagnosis typically involves a physical examination, where a doctor assesses the Characteristic rash and blisters. To confirm the diagnosis, the doctor may take a sample of blister fluid for Laboratory analysis or conduct a blood test to detect antibodies, which indicate past exposure to the Varicella-zoster virus.[15] History and physical evaluation "Shingles typically starts with a warning phase (prodrome) of fever, fatigue, and severe burning pain, Followed by a rash with blisters that appear in one to three waves over three to five days. The rash Usually affects one side of the body, within a specific nerve pathway (dermatome).

The infection has Three stages:

1. Preeruptive stage (abnormal skin sensations, pain, headaches, and light sensitivity)
2. Acute eruptive stage (blisters, symptoms, and contagiousness)
3. Chronic stage (persistent pain, numbness, and tingling)

Shingles can also affect the ear (Shingles oticus), mouth, and eye (ophthalmic zoster), leading to Complications like hearing loss, vertigo, and vision problems. The virus can spread to blood vessels, Causing damage and complications like tooth loss and osteonecrosis. In severe cases, shingles can affect The central nervous system, leading to conditions like encephalitis, paralysis, and Guillain-Barre Syndrome. Complications can include bacterial infections, scarring, nerve damage, and chronic pain (post-herpetic neuralgia)." "Herpes zoster (shingles) is typically diagnosed based on symptoms like burning pain, characteristic rash, And typical distribution. However, tests can confirm the diagnosis and rule out other conditions.

These Tests include:

- Tzanck smear (shows multinucleated giant cells)
- Direct fluorescent antibody (DFA) test
- Polymerase chain reaction (PCR) test (most reliable)
- Varicella-zoster virus-specific IgM antibody test (detects active infection)

Differential diagnosis is necessary to distinguish shingles from other conditions like:

- Herpes simplex
- Dermatitis herpetiformis
- Impetigo
- Contact dermatitis

- Candidiasis

Drug reactions

- **Insect bites**

Shingles can be distinguished from other oral blistering conditions by its one-sided involvement in Theoral cavity. The prodromal pain before the rash may be mistaken for a toothache, leading to Unnecessary dental treatment."[16]

Laboratory Test method:

1) Polymerase chain reaction

"Polymerase chain reaction (PCR) is a highly sensitive method for detecting varicella-zoster virus (VZV) DNA in various bodily fluids, including:

- Blood (whole blood, serum, plasma, peripheral blood mononuclear cells)
- Saliva
- Cerebrospinal fluid (CSF)

PCR can detect VZV DNA:

- In blood, from 5 days before to 4 days after rash eruption
- In T lymphocytes, as early as 8-10 days before eruption and persisting beyond six months
- In saliva, with high positivity rates, especially on the day of rash onset
- In CSF, with higher positivity rates than plasma samples and serological detection methods

Real-time PCR can monitor treatment effectiveness by detecting decreasing viral loads. Saliva collection Is more convenient than plasma collection, and CSF testing is invasive, making it less suitable for ordinary Patients. These findings suggest that PCR detection of VZV DNA in saliva and blood can aid in early Diagnosis and monitoring of herpes zoster, especially in patients without a rash.[17]

Procedure of PCR:

"Saliva samples were collected using a specialized kit (Omnigene-Oral) and processed as follows:

1. Shaken vigorously for 10 seconds
2. Incubated in a water bath at 50°C for 1 hour
3. DNA extracted using a QIAamp DNA mini kit
4. VZV DNA quantified using a real-time PCR kit (Gene Proof) on a Light Cycler 96 System (Roche)

The amount of VZV DNA was determined by comparing the test samples to a reference VZV DNA Standard, using the cycle threshold values.[18]

Antibody and Complement Detection:

"Antibody and complement detection can aid in shingles diagnosis. When varicella-zoster virus (VZV) Reactivates, serum antibody levels remain high and can be measured to diagnose shingles. Studies have Used various methods to detect VZV antibodies, including:

- IgM antibody-capture radioimmunoassay (MACRIA)
- Enzyme-linked immunosorbent assay (ELISA)
- Complement fixation (CF) test

Findings include:

- VZV-IgM antibodies appear after skin lesions and peak 6-10 days after rash onset, making them useful For diagnosis within 3.5 weeks

- VZV-IgG antibodies are strongly correlated with CF titers, but are less useful for early diagnosis
- CF titers increase slowly over time and may not be directly related to time of onset
- VZV-specific CF tests can be negative in some patients, but paired tests can show elevated titers Peaking around 2 weeks after onset

Proteomic Analysis and Non-coding RNA

"Researchers have used proteomic analysis and non-coding RNA studies to identify potential biomarkers For shingles (HZ) diagnosis.

3.1 Proteomic analysis:

- Identified 44 differentially expressed proteins in HZ patient plasma
- Selected six key molecules for further study
- Validated three proteins (PLG, F2, and VTN) as biomarkers for early HZ detection Non-coding RNA studies:
- Analyzed serum microRNA levels in 41 HZ patients
- Found six microRNAs (miR-190b, miR-571, miR-1276, miR-1303, miR-943, and miR-661) with Significantly increased expression in HZ patients
- Identified VZV-encoded small non-coding RNAs (sncRNAs) with potential antiviral therapy applications Future research directions:
- Large-scale, multicenter studies with repeated validation
- Acquisition of blood samples from patients before rash eruption (a challenging task)
- Investigation of blood protein expression changes in pre-eruption patients"

3.2 Inflammatory Cytokines:

Herpes zoster (HZ) neuralgia is associated with increased levels of inflammatory cytokines, including Galectin-3 and IL-6. Galectin-3, a protein involved in various biological processes, plays a role in pain Production and is elevated in HZ patients. Additionally, HZ patients exhibit reduced immunity and a Dysfunctional immune response, characterized by changes in T-lymphocyte levels. While these Inflammatory markers are elevated in patients with HZ neuralgia, further research is needed to Understand their role in early diagnosis and to determine their specificity for HZ diagnosis. Currently, There is a lack of studies comparing inflammatory factor levels between pre-eruption patients and Healthy individuals.

3.3 Non- Invasive Examination

3.3.1 High frequency Ultrasound Diagnosis:

High-frequency ultrasound is a non-invasive diagnostic tool that can visualize skin layers, subcutaneous Tissue, and nerve structures. It's commonly used for diagnosing skin conditions like tumors and Scleroderma. In shingles patients, ultrasound can detect thickening of skin, subcutaneous tissue, and Nerves, as well as nerve damage and edema. These changes occur even before the rash appears, making Ultrasound a potential tool for early diagnosis of shingles neuralgia. However, research in this area is Scarce. As ultrasound technology advances, it's likely to play a significant role in diagnosing pre-eruption Shingles neuralgia.

3.3.2 Infrared Thermal Imaging:

Infrared thermal imaging is a non-invasive technology that uses thermal infrared signals to create a heat

Map of the body, allowing for accurate temperature measurements. This technique has been widely Used in clinical research due to its convenience, speed, and lack of radiation. Infrared thermography can Detect temperature changes in the body, such as local hypothermia or high temperatures, which can Indicate various physiological processes. Research has shown that infrared thermography can aid in the early diagnosis of herpes zoster (HZ) neuralgia before the rash appears, and can even predict the Progression to postherpetic neuralgia (PHN). However, the technique may be affected by external factors Like scratching or acupuncture, and more research is needed to determine its reliability and specificity in Diagnosing shingle neuralgia.

Treatment:

The virus that stays in the body after chickenpox reactivates to produce shingles. Therefore, ask someone who has never had chickenpox to stay away from others who are infected with Shingles or chickenpox. Additionally, make sure kids practice good hand and cough hygiene to lower their chance of contracting chickenpox.

Topical agent: To relieve itching and lessen bacterial colonization on damaged skin, local treatment is required. This can be done four to six times a day by applying moist compresses or dressings soaked in tap water or 5% aluminum acetate (Burow's Solution). Calamine lotion might then be used sparingly following the compression of the Es.10 Antibiotic ointments or lotions are only effective for secondary infections of ulcerated areas. 42 individuals treated with 1% silver sulfadiazine cream shown a clear clinical response against these kinds of infected lesions in one report.[19]

Antiviral medications: If taken within 72 hours of the onset of symptoms, these medications may reduce discomfort and hasten the resolution of the condition. They might also aid in preventing postherpetic neuralgia, a pain that can develop months or years after the initial injury. Among these drugs is

Acyclovir (Zovirax)

Valacyclovir (Valtrex) and

Famciclovir (Famvir).[20]

Analgesics: Mild to somewhat powerful For the most part, systemic analgesics—such as codeine, acetaminophen, and nonsteroidal anti-inflammatory drugs—work well to manage HZ acute pain. Although there are no well-designed trials that assess these medications' effectiveness for HZ, clinical experience indicates that analgesics may reduce acute discomfort and promote.[21,22,23]

Antiviral Eye Drops: Antiviral eye drops or ointments may be provided if shingles affects the eyes (ophthalmic herpes zoster) in order to avoid complications.[24]

Complications:

The four categories of HZ complications are cutaneous, visceral, neurological, and ocular, and the chance of each category rising with age. Ocular problems are the most common after PHN, and any structure within the eye might be infected by the virus.[25]

1. **Long-term nerve pain:**

Postherpetic neuralgia, or PHN, is the most frequent long-term nerve pain problem following shingles. Even after the rash goes away, PHN might still develop in the same area as the shingles outbreak. After the rash fades away, it may persist for months or even years. PH

2. **Other serious complications:**

2.1 Facial shingles can damage the eye and result in blindness.

2.2 Bacteria can also penetrate the shingles rash.
2.3 Seldom, having shingles might also result in:

- Lung infection, or pneumonia
- Issues with hearing
- Inflammation of the brain (encephalitis)
- Deaths

2.4. Prevention & treatment of posthepatic neuralgia:

One common side effect of shingles is posthepatic neuralgia, sometimes referred to as postherpetic neuralgia (PHN) (herpes zoster). It is distinguished by ongoing nerve discomfort that persists even after the shingles outbreak has healed. Here is a quick summary of how it is treated and prevented:

2.4.1 Prevention:

Immunization: The Shingrix vaccination, which prevents shingles, is very successful in lowering the risk of shingles and postherpetic neuralgia. Adults fifty years of age and up are advised to use it. Early Treatment of Shingles: If taken as directed, antiviral drugs such as acyclovir, valacyclovir, or famciclovir can help lessen the severity and duration of shingles. There is a shingles vaccine that has been approved by the Food and Drug Administration that can lower your risk of developing PHN and shingles. For individuals 50 years of age and above, the recombinant herpes-zoster vaccination, often known as Shingrix, is advised to prevent shingles. Two to six months apart, two doses of the immunization are administered. The two-dose vaccination has a 90% success rate in preventing PHN and shingles. Vaccination results in at least four years of protection.[26]

2.4.2 Treatments:

While PHN cannot be cured, it can be managed. The majority of PHN patients experience pain that gradually gets better and goes away. The majority of people have one to three months of pain relief.[26]

2.4.3 Medication:

- Antidepressants: Serotonin-norepinephrine reuptake inhibitors, such as duloxetine, or tricyclic antidepressants, such as amitriptyline, can help control pain.
- Anticonvulsants: For nerve pain, drugs such as gabapentin or pregabalin are frequently prescribed.
- Topical Treatments: Localized relief may be obtained with lidocaine patches or capsaicin lotion.
- Opioids: Despite their potential for dependency, opioids are usually taken cautiously, even when prescribed for severe pain.[27]

i. Pain Management:

- Physical therapy: May aid in pain relief and functional enhancement.
- TENS (Transcutaneous Electrical Nerve Stimulation): An apparatus that reduces pain by use of electrical currents.
- Nerve Blocks: Temporary relief may be obtained by injecting steroids or anesthetics into the area around the injured nerves.
- Lifestyle Modifications: Managing stress, maintaining a balanced diet, and getting enough sleep can all help with general pain relief and wellbeing.

b. Vision problems:

A number of vision issues can arise from Shingles when it affects the eye. Herpes zoster ophthalmicus is the term used to describe this condition (HZO). According to experts, HZO affects 10% to 20% of shingles

patients. Usually beginning two to four weeks after the shingles rash initially emerges, HZO symptoms. It may result in a range of ocular issues, including:

- conjunctivitis, or pink eye as it is popularly called
- keratitis, or inflammation of the cornea, the transparent outer layer of the eye;
- episcleritis, or inflammation of the tissue between your eyelid and the white of your eye
- Uveitis, an inflammation of the uvea, the middle layer of the eye
- Optic neuritis, an inflammation of the optic nerve responsible for transmitting signals from the eyes to the brain
- damage to the retina, the portion of the eye that translates light into electrical signals; glaucoma, which can result in vision loss due to elevated intraocular pressure Because HZO effects have the potential to cause visual loss, it is an emergency. Antiviral drugs are used as eye drops or as an oral treatment. Moreover, corticosteroids can aid in lowering inflammation.[28]

Prevention:

1. Vaccination:

There are two vaccines available to prevent shingles:

1. Zostavax/ attenuated vaccine:

- Suitable for people 50 years of age and above;
- One dosage;
- provides approximately five years of shingles Prevention.

2. Shingrix/ The recombinant vaccination:

- Suitable for those 50 years of age and above
- Comes in two doses spaced 2–6 months apart
- Offers long-term protection (more than 5 years)

1. Zostavax

For immunocompromised people 19 years of age and older, the CDC advises administering two doses of RZV to prevent shingles in those who are or will be immunodeficient or immunosuppressed due to illness or treatment. Usually, two to six months should pass between the first and second dose of RZV. Nonetheless, the second dose can be given 1-2 months after the first for those who are or will be immunodeficient or immunosuppressed and who would benefit from finishing the series sooner. As of November18,2020, Zostavax is no longer prescribed in the United States. When administering the Shingrix vaccination, take into account the patient's age and the date of their Zostavax injection. Research looked at the safety of the Shingrix vaccine five years or more following the Zostavax vaccination. Although shorter intervals were not investigated, there is no evidence to suggest that administering Shingrix to a patient fewer than five years after they got Zostavax would compromise safety or efficacy.[29]

The following are potential negative effects of the Zostavax/ live attenuated zoster vaccination:

1. Injection site pain, redness, swelling, or itching (up to 67% of patients)
2. Fatigue (in as many as 47% of cases)
3. Pain in the head (37% of recipients)
4. Fever (in as many as 9% of cases)
5. Up to 7% of recipients experience nausea or vomiting.
6. Rare allergic responses
7. A uncommon rash resembling Shingles

8. Rarely, hives or itching
9. Rarely, swollen lymph nodes
10. Rare but serious adverse effects such as:

- Anaphylaxis
- Angioedema
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis

The majority of adverse effects are minor to moderate and go away in a few days.

1. Shingrix:

Research indicates that Shingrix is safe. During clinical trials, there were no significant adverse events linked to Shingrix. Strong defense against shingles and postherpetic neuralgia (PHN), the most frequent consequence of shingles, is offered with Shingrix.

Possible side effects:

Your immune system is strongly triggered by Shingrix, which aids in fortifying your body's defenses against shingles. As a result, the vaccine may cause brief adverse effects, which typically go away after two to three days. Your capacity to perform regular everyday tasks may be impacted by this. Even though you can feel discomfort for a few days following the application of Shingrix, this pain will not be as bad as shingles and its complications. After receiving Shingrix, the majority of patients experienced mild to moderate arm pain; a small percentage also experienced redness and edema at the injection site. Some reported headaches, shivers, fever, stomach aches, and nausea in addition to fatigue and muscle aches. Some Shingrix users reported adverse effects that made it difficult for them to go about their daily lives. The symptoms subsided on their own in two to three days. Adverse effects were more prevalent in younger individuals. It's possible that you will react to one or both of the Shindrix doses. You might decide to take acetaminophen or ibuprofen, two over-the-counter pain relievers, if you have adverse effects.[30]

Vaccine available to prevent shingles:

For healthy individuals 50 years of age and older, the Shingrix vaccine is advised.

Even so, you ought to receive the Shingrix vaccination if:

- You have already experienced shingles.
- You have received a prior dose of the live zoster vaccine, Zostavax. It is recommended to wait at least eight weeks after receiving the Zostavax vaccination before receiving the Shingrix vaccination.[31]
- If you've previously experienced shingles, Shingrix can help avoid further bouts.
- You've already had the Zostavax vaccination: If you have the live zoster vaccine Zostavax, wait at least eight weeks before receiving the Shingrix vaccination. Shingrix offers protection that lasts longer.
- You're not sure whether you've had chickenpox: Shingrix can still prevent shingles.
- You're taking immune-suppressive medications: As always, check with your physician, but Shigraph is normally advised.
- If you suffer from long-term health issues (such as diabetes or renal illness), Shingrix is still advised.
- If you are fifty years of age or older, Shingrix is appropriate for you.

Not recommended to have the Shingrix vaccine:

A vaccination called Shingrix is intended to prevent shingles, also known as herpes zoster, and its associated consequences. Some people, on the other hand, ought not to take the Shingrix vaccine or ought to speak with their doctor beforehand.

Among them are:

- Have a high fever and are unwell.
- Have not tested positive for varicella-zoster virus immunity; instead, receive the chickenpox vaccination.
- Are intolerant of any vaccination ingredients: In case you are allergic, speak with your physician. Have you ever experienced a serious allergic reaction to this vaccination or any of its ingredients.
- Women who are expecting or nursing: Because there is little safety information, speak with your doctor.
- Immunocompromised people: People who take immunosuppressive medications, have cancer, HIV/AIDS, or other immune system disorders should speak with their healthcare physician.
- History of adverse reactions: If you've previously received vaccines or vaccine components and experienced serious allergic responses. (For example, anaphylaxis) Speak with your doctor.
- Currently suffering from an active shingles infection: Hold off on getting the vaccination until the infection has cleared up.
- Do you presently take antiviral drugs such as famciclovir, valacyclovir, or acyclovir, If you are taking antiviral drugs for shingles or another ailment, speak with your doctor.
- Age under 50: Shingrix is appropriate for people 50 years of age and beyond. If you are under 50, speak with your doctor.[20]

It is imperative that you speak with your healthcare practitioner about any worries you may have about getting Shingrix. They will evaluate your particular circumstance and offer advice.

Healthy lifestyle for prevention of Shingles:

Keeping your immune system strong and controlling your stress levels are key to preventing shingles. The following tactics can help with this:

1. 1.Obtain Vaccination: The Shingrix vaccination effectively lowers the chance of contracting Shingles and its sequelae. Adults fifty years of age and up are advised to use it.
2. Keep a Balanced Diet: To boost immunity, eat a diet high in fruits, vegetables, whole grains, and lean meats.
3. Work Out Frequently: Physical activity on a regular basis strengthens your immune system and improves your general health.
4. Control Stress: Excessive stress might impair immunity. Engage in stress-relieving activities like yoga, meditation, or mindfulness.
5. Get Enough Sleep: To ensure that your immune system is operating at its best, try to get 7-9 hours of good sleep every night.
6. Maintain Good Hygiene: To prevent infections, stay away from those who are sick with chickenpox or shingles and practice good personal hygiene.
7. Remain Hydrated: Eating a lot of water promotes general health and optimal bodily function.
8. By implementing these routines into your everyday life, you can reduce your chance of getting shingles.

Avoid close contact for preventing shingles:

The varicella-zoster virus, which causes shingles, can be stopped from spreading by avoiding close contact with shingles patients:

1. Avoid touching: Keep your hands off a person who has shingles' rash or blisters.
2. Refrain from sharing personal items: Never give someone who has shingles your towels, clothes, or utensils.
3. Keep your distance: To lessen the likelihood of close contact, stay at least three feet away from someone who has shingles.
4. Steer clear of contacting those who are weak: Stay away from these people if you have shingles:

- Pregnant women
- Infants
- Individuals with impaired immune systems (such as those with HIV/AIDS, cancer, or immunosuppressive medications)
- Those who have never had chickenpox or who have not received the Vaccination.

5. Cover the rash: To lower the chance of transmission, if you have shingles, cover the rash with clothing or a dressing.
6. Wash your hands: After handling someone who has shingles or their personal belongings, wash your hands often with soap and water.

Recall that the virus that causes shingles mostly spreads through direct contact with the rash, making it less contagious than chickenpox. You can lower the chance of transmission by implementing these safety measures.

Manage chronic conditions:

In order to avoid and lessen the severity of shingles, managing chronic diseases is essential. Here are some pointers:

1. Diabetes management: Control your blood sugar levels with food, exercise, and, if necessary, medication.
2. Managing hypertension: Keep an eye on your blood pressure and regulate it with medication (if required).
3. Managing renal disease: To manage kidney disease, adhere to your treatment plan, which includes food and medicines.
4. Managing liver disease: To manage liver disease, adhere to your treatment plan, which may include medication and lifestyle modifications.
5. Management of autoimmune illnesses: To control autoimmune disorders such as rheumatoid arthritis or lupus, adhere to your treatment plan, which may include medication and lifestyle modifications.
6. Cancer management: To effectively manage cancer, adhere to your treatment plan, which may include radiation, chemotherapy, and medication.
7. HIV/AIDS management: To manage HIV/AIDS, adhere to your treatment plan, which may include antiretroviral therapy.
8. Routine health check-ups: See your doctor on a regular basis to have your chronic problems monitored and to have your treatment plan modified as necessary.
9. Adherence to medication: Take your meds exactly as directed by your doctor.

10. Habits of a healthy lifestyle: To aid in the treatment of chronic illnesses, lead a healthy lifestyle that includes a balanced diet, frequent exercise, stress reduction, and enough sleep.

By taking good care of your chronic illnesses, you can lower your chance of getting shingles and lessen the severity of the disease if you do.

Risk Factors:

The primary risk factor for HZ is advanced age.38, 39, 40, 41, 42, 43, and 44 The incidence of HZ in the general population is two to three cases per 1,000 patients annually. In the general population, the lifetime risk is approximately 30%, and at least 50% of those who live to be 85 years old will have experienced HZ. With an odds ratio (OR) of 1.20 (1.10–1.31) per five years for individuals over 65, the lifetime risk rises with age.[31]

Following shingles, the following factors may increase the risk of postherpetic neuralgia:

- Age. You are not 60 years old.
- The severity of the shingles case. You were unable to perform your everyday tasks due to a significant rash and agony.
- Additional ailments. You suffer from a chronic illness, like diabetes.
- The location of the shingles. On your face or torso, you had shingles.
- A postponement of shingles therapy. You did not begin antiviral medication therapy within 72 hours after the onset of your rash.
- No vaccination against shingles. You had not received a shingles vaccination.[32]
- Vaccination against Chickenpox:

To prevent chickenpox, children between the ages of 12 and 18 months are routinely administered the Varivax vaccine. It is advised by experts for both adults and older kids who have never had chickenpox. Although the vaccine does not guarantee complete protection, it significantly lowers the likelihood of consequences and the severity of the disease if it does arise.[33]

- Immune system weakness: conditions like HIV/AIDS or immunosuppressive medication.
- Stress: The immune system can be weakened by mental or physical stress.
- Specific Medication: This includes immunosuppressive medications and steroids.
- Medical Conditions: This includes autoimmune disorders and cancer.
- Recent Organ Transplant: Patients frequently take immune-suppressive drugs.
- Trauma: Injuries or trauma to the body might cause shingles in the afflicted area.
- Pregnancy: Immune system alterations during pregnancy may make a person more susceptible.
- varicella vaccine has been associated with a very small number of milder episodes of shingles.[24]

Reference:

1. Gershon, A. A., Gershon, M. D., Breuer, J., Levin, M. J., Oaklander, A. L., & Griffiths, P. D. (2010). Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. Journal of Clinical Virology, 48, S2–S7. https://doi.org/10.1016/s1386-6532(10)70002-0
2. Nair PA, Patel BC. Herpes Zoster. [Updated 2023 Sep 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441824/
3. Megan Soliman, MD ,Erica Roth ,"Is Shingles Contagious? Plus, How It Spreads" January 3, 2024.
4. Zartash Zafar Khan, MD, FACP " Varicella-Zoster Virus (VZV)" Updated: Sep 30, 2022

5. Zerboni L, Sen N, Oliver SL, Arvin AM. Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol. 2014 Mar;12(3):197-210. Doi: 10.1038/nrmicro3215. Epub 2014 Feb 10. PMID: 24509782; PMCID: PMC4066823.
6. de Jong MD, Weel JF, Schuurman T, Wertheim-van Dillen PM, Boom R. Quantitation of varicella-zoster virus DNA in whole blood, plasma, and serum by PCR and electrochemiluminescence. J Clin Microbiol. 2000 Jul;38(7):2568-73. Doi: 10.1128/JCM.38.7.2568-2573.2000. PMID: 10878045; PMCID: PMC86970.
7. Chelsea Gerada, Tessa M. Campbell, Jarrod J. Kennedy, Brian P. McSharry, Megan Steain, Barry Slobedman and Allison Abendroth " Manipulation of the Innate Immune Response by Varicella Zoster Virus" Frontiers In Immunology. Published: 24 January 2020 Volume 11 | Article 1 Doi: 10.3389/fimmu.2020.00001.
8. Michael N. Oxman, MD " Herpes Zoster Pathogenesis and Cell-Mediated Immunity and Immunosenescence" J Am Osteopath Assoc. 2009;109(suppl 2):S13-S17
9. Folusakin Ayoade; Sandeep Kumar."Varicella-Zoster Virus (Chickenpox)" October 15, 2022.
10. Anant Patil , Mohamad Goldust ,And Uwe Wollina . " Herpes zoster: A Review of Clinical Manifestations And Management" Viruses 2022, 14, 192. https://doi.org/10.3390/v14020192
11. Elsam Koshy, Lu Mengting, Hanasha Kumar, Wu Jianbo," Epidemiology, treatment and prevention of Herpes zoster: A comprehensive review" © 2018 Indian Journal of Dermatology, Venereology and Leprology | Published by Wolters Kluwer – Medknow.
12. Anne A. Gershon,Michael D. Gershon,Judith Breuer,Myron J. Levin,d Anne Louise Oaklander,e and Paul D. Griffiths," Advances in the understanding of the pathogenesis and epidemiology of herpes zoster" J Clin Virol. 2010 May; 48(Suppl 1): S2–S7. Doi: 10.1016/S1386-6532(10)70002-0 PMCID: PMC5391040NIHMSID: NIHMS854799PMID: 20510263.
13. Bardach AE, Palermo C, Alconada T, Sandoval M, Balan DJ, Nieto Guevara J, Gómez J, Ciapponi A. Herpes zoster epidemiology in Latin America: A systematic review and meta-analysis. PLoS One. 2021 Aug 12;16(8):e0255877. Doi: 10.1371/journal.pone.0255877. PMID: 34383851; PMCID: PMC8360515.
14. https://en.m.wikipedia.org/wiki/Varicella_zoster_virus
15. Avi Varma, MD, MPH, AAHIVS, FAAFP, Hannah Nichols. Shingles (Herpes Zoster). August 5,2024.
16. Pragya A. Nair; Bhupendra C. Patel. "Herpes Zoster". National Laboratory of Medicine. September 4, 2023. https://www.ncbi.nlm.nih.gov/
17. Han-Rui Fan,#1 En-Ming Zhang,#1 Yong Fei,corresponding author2 Bing Huang,2,Ming Yao2 " Early Diagnosis of Herpes Zoster Neuralgia: A Narrative Review" National Laboratory of Medicine. 2023 May 2 doi: 10.1007/s40122-023-00510-4 PMCID: PMC10289968PMID: 37129752
18. Sungim Choi,1,* Song Mi Moon,2,* Ji-Soo Kwon,3 Sung-Han Kim,3 and Seong Yeon Parkcorresponding Author1" Diagnostic Usefulness of Varicella Zoster Virus-Specific Immunoglobulin (Ig) A and IgG in Patients With Herpes Zoster" National Laboratory of Medicine. 2023 Jan 9; 38(2): e7. Published online 2022 Dec 8. Doi:10.3346/jkms.2023.38.e7PMCID: PMC9829510PMID: 36625171
19. Montes LF, Muchinik G, Fox CLJr. Response Ofvaricella Zoster virus and herpes zoster to silver Sulfadiazine. Cubs 1986;38:363-5.
20. Shingles. (2024b, May 1). Retrieved from https://my.clevelandclinic.org/health/diseases/11036-shingles

21. Portenoy RK, Duma C, Foley KM. Acute Herpetic and Postherpetic neuralgia: clinical Review and current Management Ann Naa! 1986;20:651-64.
22. CannihaelJK. Treatment ofhexpes zoster and Postherpetic neuralia. Am FeanPhysicim 1991;44:203-10.
23. SatterthwaiteJR. Postherpetic neuralgia. In:Tollinson CD, editor. Handbook ofdffonipain Mnagemen. Baltimore: Williams and Wilkdns, 1989:460-71. https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.ncbi.nlm.nih.gov/pmc/articlEs/PMC2380046/pdf/canfamphys000960115.pdf&ved=2ahUKEwjmutL166IAxXeVmwGHSW_MpoQFnoECBsQAQ&us”=AOvVaw1IHtScF4GSm0iCFhT7HU0Sa
24. Shingles: Causes, Risk Factors, Symptoms, Treatment. (n.d.-b). Retrieved from https://continentalhospitals.com/diseases/shingles/
25. Gershon, A. A., Gershon, M. D., Breuer, J., Levin, M. J., Oaklander, A. L., & Griffiths, P. D. (2010). Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. Journal of Clinical Virology, 48, S2–S7. https://doi.org/10.1016/s1386-6532(10)70002-0
26. Postherpetic Neuralgia. (2024b, May 1). Retrieved from https://my.clevelandclinic.org/health/diseases/12093-postherpetic-neuralgia#management-and-treatment
27. Admin. (2021b, August 13). Postherpetic Neuralgia. Retrieved from https://novusspinecenter.com/pain-conditions/postherpetic-Neuralgia
28. Seladi-Schulman, J. (2024b, February 23). What Are the Possible Complications of Shingles? Retrieved from https://www.healthline.com/health/shingles-complications#postherpetic-neuralgia
29. Shingles Vaccine Recommendations. (2024b, July 19). Retrieved from https://www.cdc.gov/shingles/hcp/vaccine-considerations/index.html
30. Shingles Vaccination. (2024b, July 19). Retrieved from https://www.cdc.gov/shingles/vaccines/index.html#:~:text=The%20vaccine%20is%20safe%20and,most%20common%20complicatioN%20of%20shingles
31. Gershon, A. A., Gershon, M. D., Breuer, J., Levin, M. J., Oaklander, A. L., & Griffiths, P. D. (2010). Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. Journal of Clinical Virology, 48, S2–S7. https://doi.org/10.1016/s1386-6532(10)70002-0
32. Postherpetic neuralgia – Symptoms and causes – Mayo Clinic. (2023b,February 10). Retrieved from https://www.mayoclinic.org/diseases-Conditions/postherpetic-neuralgia/symptoms-causes/syc-20376588
33. May, B. (2018b, January 11). What is postherpetic neuralgia? Retrieved From https://www.medicalnewstoday.com/articles/160253#prevention